LENZ LENZ Therapeutics Forecast, Technical & Fundamental Analysis
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products... Show more
LENZ is expected to report earnings to fall 25.76% to -98 cents per share on August 19
Q2'26
Est.
$-0.98
Q1'26
Missed
by $0.15
Q4'25
Missed
by $0.40
Q3'25
Missed
by $0.19
Q2'25
Beat
by $0.08
The last earnings report on May 11 showed earnings per share of -132 cents, missing the estimate of -116 cents. With 146.51K shares outstanding, the current market capitalization sits at 212.90M.
A.I.dvisor indicates that over the last year, LENZ has been loosely correlated with MLTX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LENZ jumps, then MLTX could also see price increases.
Momentum Indicator for LENZ turns negative, indicating new downward trend
LENZ saw its Momentum Indicator move below the 0 level on June 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In of the 88 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for LENZ turned negative on June 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LENZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LENZ's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LENZ advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
LENZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.864) is normal, around the industry mean (19.567). P/E Ratio (48.030) is within average values for comparable stocks, (35.932). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.687). LENZ has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (9.634) is also within normal values, averaging (355.865).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LENZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LENZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
